Biologics

DSM Unveils VitroStealth™ Coating Technology

GELEEN, The Netherlands–(BUSINESS WIRE)–DSM Biomedical, a global leader in biomedical materials, today announced the development of VitroStealth™, a breakthrough non-biofouling (NBF) coating technology. Specifically developed to combine state of the art non-biofouling properties with high durability and fast processing, VitroStealth™ coating is scratch resistant and reduces unwanted protein absorption and cellular adhesion on surfaces.

“While the main application focus at this time for VitroStealth™ coating is in life science consumables, pre-analytics, and point of care diagnostics, we are excited about the many other areas that the technology can significantly impact,” said Steve Hartig, President of DSM Biomedical. “We currently are investigating the scope of this technology for in-vivo medical applications and see a future for this coating technology in several other markets.”

To develop the medical coating technology, DSM Biomedical leveraged advances in scratch resistant coatings developed by its parent organization DSM for use in displays and other non-medical applications. By extending DSM’s leading hard coat technology to medical applications, DSM is aiming to offer the medical device and pharmaceutical industry the ability to decrease the likelihood of surface contamination and improve assay sensitivity, reproducibility and ultimately the reliability of medical consumables and point of care diagnostic tools. Application includes pre-analytical blood collection devices where VitroStealthTM coating eliminates surface mediated hemolysis and leads to clean, reproducible and thus reliable serum or plasma samples for the clinical laboratory. In diagnostics, VitroStealthTM coating increases signal to noise ratio as the analyte is not partially lost by adsorption to the surface of the device. Furthermore, due to its highly hydrophilic character the coating increases the capillary flow of analytes in micro-fluidic point of care devices.

“Medical experts do not leave much to chance. They need analytical and diagnostic tools that are reliable and leave no doubts regarding their efficacy,” said John Marugg, Business Director for Medical Coatings, DSM Biomedical. “It was critical that we expand upon DSM’s existing technology to provide the medical community with a coating technology whose durability and reliability are unparalleled.”

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button